SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001516551-23-000103
Filing Date
2023-12-05
Accepted
2023-12-05 17:04:04
Documents
15
Period of Report
2023-11-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K skye-20231129.htm   iXBRL 8-K 44683
2 EX-10.1 skye-8xkdecember2023ex101t.htm EX-10.1 378082
3 EX-10.2 skye-8xkdecember2023ex102o.htm EX-10.2 106717
4 EX-99.1 a2311228skyenrtautomer.htm EX-99.1 17200
  Complete submission text file 0001516551-23-000103.txt   764165

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT skye-20231129.xsd EX-101.SCH 1923
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT skye-20231129_lab.xml EX-101.LAB 23083
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT skye-20231129_pre.xml EX-101.PRE 12063
9 EXTRACTED XBRL INSTANCE DOCUMENT skye-20231129_htm.xml XML 2537
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Filer) CIK: 0001516551 (see all company filings)

IRS No.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-55136 | Film No.: 231467466
SIC: 2834 Pharmaceutical Preparations